Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
NCT05082584 · Akebia Therapeutics · PHASE3 · withdrawn · last registry update 2025-10-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Akebia Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGLN1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-04Also stopped (terminated): GlaxoSmithKline, GSK1278863 + Placebo (NCT02075463)
- 2026-07-23Phase 3 first posted: Kyntra Bio, Roxadustat + Placebo (NCT07722988)
- 2026-07-07Also stopped (withdrawn): Peking Union Medical College Hospital, Roxadustat in combination with retinoic acid (NCT06020833)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Enarodustat + Cyclosporin (CSA) (NCT07522996)
- 2026-05-04Phase 3 first posted: Geoff Block, Epoetin alga (Epogen)/vadadustat (NCT07565701)
- 2026-04-23Phase 3 first posted: Peking Union Medical College Hospital, Enarodustat + Cyclosporine (CsA) (NCT07548671)
- 2026-04-13Phase 3 first posted: Peking Union Medical College Hospital, Enarodustat + Cyclosporin (CSA) (NCT07522996)
- 2025-12-23Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Daprodustat + Darbepoetin alfa (NCT07300111)
- 2025-12-09Also stopped (terminated): Peking Union Medical College Hospital, Roxadustat + Placebo (NCT05010460)
- 2025-11-10Results posted on the registry: GlaxoSmithKline, Daprodustat (NCT05682326)
- 2025-10-01Also stopped (withdrawn): Akebia Therapeutics, vadadustat (NCT05082571)
- 2025-07-25Phase 3 first posted: Paul Potnuru, Vadadustat 900mg + Vadadustat 1200mg (NCT07086755)
- 2025-05-22Results posted on the registry: Akebia Therapeutics, Vadadustat + Darbepoetin alfa (NCT04313153)
- 2025-03-30Phase 3 first posted: Akebia Therapeutics, Erythropoiesis-Stimulating Agent (ESA) + Vadadustat (NCT06901505)
- 2025-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, vadadustat + placebo (NCT04478071)
- 2025-01-15Results posted on the registry: Akebia Therapeutics, Vadadustat + Mircera® (NCT04707768)
- 2025-01-13Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Roxadustat (NCT06772272)
- 2024-12-06Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL-0951 tablets + rHuEPO injection (NCT06720025)
- 2024-12-06Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL-0951 tablets (NCT06720233)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision